Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities

Khunti, Kamlesh; Heerspink, Hiddo J L; Lam, Carolyn S.P.; Nicolucci, Antonio; Ramírez, Laura; Surmont, Filip; Fenici, Peter; Kosiborod, Mikhail

doi:10.1016/j.jdiacomp.2021.108077

Cited by 5 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The trend is expected to continue, with a projected increase of 55%, from 425 million in 2019 to 700 million in 2045 ( Saeedi et al., 2019 ). In 2019, the global prevalence of diabetes mellitus was 9.3%, with type II diabetes accounting for more than 90% of all diabetes mellitus cases, while type I diabetes and gestational diabetes accounted for less than 10% of all cases ( Khunti et al., 2021 ).…”

Section: Introductionmentioning

confidence: 99%

“…The prevalence of type II diabetes is comparable in high-income and low and middle-income countries. Still, the projected increase in prevalence is expected to hit low and middle-income countries the hardest ( Khunti et al., 2021 ). The populations in low and middle-income countries face challenges related to treatment inaccessibility and cost barriers, which make it difficult to obtain or sustain lifelong treatment for chronic conditions ( Lemos Macedo et al., 2021 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Self-management practices for preventing complications of type II diabetes mellitus in low and middle-income countries: A scoping review

Maina

Reid

2023

International Journal of Nursing Studies Advances

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Self-management practices for preventing complications of type II diabetes mellitus in low and middle-income countries: A scoping review

Maina

Reid

2023

International Journal of Nursing Studies Advances

View full text Add to dashboard Cite

“…The healthcare systems differ between Japan and other countries, and the clinical characteristics differ between Japanese and Caucasian patients with T2DM [ 44 – 46 ]. In addition, biguanides are predominantly used as the first-line GLD in Western countries, whereas DPP4i are the most commonly prescribed initial GLD in Japan [ 47 , 48 ]. Considering these differences, the health economic impact of antidiabetic drugs in Japanese patients should be assessed using Japanese data.…”

Section: Discussionmentioning

confidence: 99%

Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium–Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan

et al. 2022

View full text Add to dashboard Cite

Introduction Many patients with type 2 diabetes mellitus (T2DM) suffer from complications that impose substantial burdens on prognosis and medical costs. Accumulating evidence has demonstrated the clinical benefit of sodium–glucose cotransporter 2 inhibitors (SGLT2i) on cardiovascular and renal complications. However, the health economic impact of SGLT2i remains unclear. The aim of this study was to evaluate the cost-effectiveness of initiating antidiabetic therapy with an SGLT2i using Japanese real-world data. Methods We constructed a natural history model incorporating heart failure (HF), myocardial infarction, stroke, chronic kidney disease, and end-stage renal disease (ESRD) as complications. The target population comprised patients with T2DM who newly initiated their first oral glucose-lowering drugs. By using a population-based microsimulation, we estimated the 10-year medical costs in Japanese yen (JPY) and outcomes (hospitalization for/development of complications and quality-adjusted life years [QALY]) for patients who initiated antidiabetic therapy with an SGLT2i or conventional therapy. Sensitivity analyses included a probabilistic sensitivity analysis (PSA) with 1,000,000 iterations. Results In the base-case analysis, the total medical cost per person was JPY 1,638,806 versus JPY 1,825,033 and the QALYs were 8.732 versus 8.513 for the SGLT2i strategy versus the conventional strategy, respectively. Thus, initiating treatment with an SGLT2i was dominant, more effective (QALY gain), and lower cost. When treating 10,000 patients, the SGLT2i strategy would reduce all-cause deaths by 410 (552 vs 962), HF events by 201 (897 vs 1098), and ESRD events by 16 (16 vs 32) versus the conventional strategy. The PSA revealed that the probability of dominance for initiating SGLT2i therapy was 90.5%, demonstrating the robustness of the results. Conclusion Our results suggest that initiating T2DM treatment with SGLT2i, aimed at managing cardiovascular and renal complications from the early stages of diabetes, can improve the clinical outcome and reduce cost burden of T2DM.

show abstract

“…To get glucose into cells, insulin is needed. In people with diabetes, the body does not have insulin (Type 1) diabetes [7] or the insulin is inadequate (Type 2) [8].…”

Section: Introductionmentioning

confidence: 99%

Monitoring and Controlling System to Improve Health Services in Diabetes Mellitus: Research and Development Study

Amirudin,

Widowati,

Sudiarto

et al. 2023

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Diabetes mellitus (DM) is a chronic disease caused by the inability of the pancreas to produce insulin or the body cannot use the insulin it produces effectively. Pekalongan City is one of the cities in Indonesia with a high prevalence of DM. The number of DM sufferers is caused by heredity, unhealthy lifestyle. AIM: The aim of the study was to create a website-based service system (e-health) that can assist the community in conducting consultation and monitoring activities for people with DM. METHODS: The method used is research and development where data and information are obtained by conducting observations, interviews and sampling both to health consultants, DM sufferers and the people of Pekalongan City. Consultants or health teams include doctors, nutritionists, psychologists and nurses. The number of people with DM was 40 respondents. RESULTS: The number of DM sufferers in Pekalongan City was 12,132 people consisting of 100 people with type-1 DM and 12,032 type-2 DM. A total of 66.7% of respondents experienced DM from heredity and 33.3% due to lifestyle and diet. As many as 48% of respondents experienced DM for <1 year, 32% between 1 and 3 years, 4% between 3 and 5 years, and 16% more than 5 years. Most (65%) respondents need online services, 10.3% really need it, 13.8% do not need it, and 10.3% do not need it. Most of the respondents needed consultation as much (56.7%), 10% essential, 13.3% less necessary, and 20% not necessary. Most require consultation with a team of health workers, as much as 62.5%, 15.6% very necessary, and 21.9% less necessary. CONCLUSION: Web-based health information system (e-health) can provide easy access for DM sufferers needed in education, consultation and monitoring, so as to reduce the number of DM sufferers in Pekalongan City.

show abstract

Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities

Cited by 5 publications

References 34 publications

Self-management practices for preventing complications of type II diabetes mellitus in low and middle-income countries: A scoping review

Self-management practices for preventing complications of type II diabetes mellitus in low and middle-income countries: A scoping review

Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium–Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan

Monitoring and Controlling System to Improve Health Services in Diabetes Mellitus: Research and Development Study

Contact Info

Product

Resources

About